Multidrug Resistance Reversal Activity of Methanol Extracts from Basidiomycete Mushrooms in Cancer Cells

  • Received : 2012.09.02
  • Accepted : 2012.11.09
  • Published : 2012.12.31

Abstract

Mushrooms have a long history of use in traditional medicine, and hundreds of novel constituents in mushrooms with miraculous biological properties have been identified recently. Although diverse effects for medicinal use of mushrooms such as anticancer activity are proven, their reversal activities of drug resistance in cancer cells was rarely reported so far. In the search for novel medicinal use of mushrooms, we tested the multidrug resistance (MDR) reversal activities of diverse mushrooms collected from Korea. Among, the mushroom extracts tested, Cantharellus cibarius (M02) and Russula emetica (M12) revealed MDR reversal activities of paclitaxel in the P-glycoprotein (Pgp)-positive HCT15 and MES-SA/dX5 cancer cells, but not in the Pgp-negative A549 and MES-SA cancer cells. In addition, these mushrooms also enhanced the cytotoxicity of doxorubicin, another well-kwown Pgp-associated anticancer drug against MES-SA/DX5 cells, but not against MES-SA cells. Meanwhile, the cytotoxicity of cisplatin, a well-known Pgp-non-associated anticancer drug, was not affected by the mushrooms all the cells tested. From these results, we suspected that some ingredients of M02 and M12 have Pgp-associated MDR reversal activities.

Keywords

References

  1. Choi, S.U., Kim, N.Y., Choi, E.J., Kim, K.H., and Lee, C.O., Establishment of doxorubicin-resistant subline derived form HCT15 human colorectal cancer cells. Arch Pharm Res 19, 342-347 (1996). https://doi.org/10.1007/BF02976376
  2. Lum, B.L., Gosland, M.P., Kaubisch, S., and Sikic, B.I., Molecular target in oncology: implication of the multidrug resistance gene. Pharmacotherapy 13, 88-109 (1993).
  3. Min, Y.D., Kwon, H.C., Yang, M.C., Lee, K.H., Choi, S.U., and Lee, K.R., Isolation of limonoids and alkaloids from Phellodendron amurense and their multidrug rresistance (MDR) reversal activity. Arch Pharm Res 30, 58-63 (2007). https://doi.org/10.1007/BF02977779
  4. Patel, S., and Goyal, A., Recent developments in mushrooms as anticancer therapeutics: a review. 3 Biotech 2, 1-15 (2012).
  5. Ryu, S.Y., Choi, S.U., Lee, C.O., and Zee O.P., Antitumor activity of Psoralea corylifolia. Arch Pharm Res 15, 356-359 (1992). https://doi.org/10.1007/BF02974112
  6. Shamtsyan, M., Konusova, V., Maksimova, Y., Goloshchev, A., Panchenko, A., Simbirtsev, A., Petrishchev, N., and Denisova, N., Immunomodulating and anti-tumor action of extracts of several mushrooms. J Biotechnol 113, 77-83 (2004). https://doi.org/10.1016/j.jbiotec.2004.04.034
  7. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S., and Boyd, M.R., New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82, 1107-1012 (1990). https://doi.org/10.1093/jnci/82.13.1107
  8. Ueda, K., Cardarelli, G., Gottesman, M.M., and Pastan, I., Expression of a full length cDNA for the human MDR-1 gene conference resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84, 3004-3008 (1987). https://doi.org/10.1073/pnas.84.9.3004
  9. Weso owska, O., Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol 58, 433-448 (2011).
  10. Xu, L. and Bao, H., Purification and inhibiting effects on smmc-7721 cell and mice-bearing h22 tumor of ${\alpha}$-amanitin (${\alpha}$-ama). Mycosystema 29, 138-142 (2010).